The intellectual property will enhance Liberate Bio’s LNP platform for selective programming of monocytes and macrophages.

Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, announces that it has secured exclusive and non-exclusive licenses to key ...

Hormone-regulated immune cells produce IL-10 to resolve pain more effectively in males, offering a potential new target for non-opioid chronic pain treatments.

Why do diabetic wounds refuse to heal? A new scientific review highlights how disruptions in the timing and behavior of ...

Researchers identify specific immune markers, like activated monocytes and cytokines, that drive cognitive decline after viral infections across various diseases.

Scientists identified a gene switch that helps immune cells fully mature, allowing them to clean up tissues and keep our organs healthy.

In mice, the loss of long-lived resident macrophages in eye tissue disrupts pressure control, suggesting a potential new target for glaucoma treatment.

What impact does a viral infection have on our memory, attention, and concentration? The COVID-19 pandemic has reignited interest in this question, which has now been extended to other infections such ...

A selective cytopheretic device for pediatrics demonstrated safety and potential benefit in 21 pediatric patients with life-threatening sepsis-associated AKI requiring kidney replacement therapy, ...

Completion of enrollment marks a key milestone toward satisfying FDA post-approval requirements. DENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Na ...